Toxicity Management in Patients Receiving mTOR Inhibitors

A discussion on the toxicities associated with mTOR inhibitors and which patients with PEComa would be considered good candidates.

EP: 1.Introduction to PEComas

EP: 2.Current Treatment Landscape of PEComas

EP: 3.Systemic Therapy in Malignant PEComas

EP: 4.Case 1: Uterine PEComa with a TSC2 Mutation

EP: 5.The AMPECT Trial: Nab-sirolimus in PEComa

Now Viewing

EP: 6.Toxicity Management in Patients Receiving mTOR Inhibitors

EP: 7.Treatment Options for PEComas After Progression on Nab-Sirolimus

EP: 8.Case 2: Hormone Receptor Positive Uterine PEComa

EP: 9.Case 3: Retroperitoneal PEComa

EP: 10.The Future of Research in PEComas

Related Videos